Enhanced anti-tumor efficacy of hyaluronic acid modified nanocomposites combined with sonochemotherapy against subcutaneous and metastatic breast tumors

Wu, Pengying; Sun, Yue; Dong, Wei; Zhou, Huige; Guo, Shifang; Zhang, Lei; Wang, Xiaobing; Wan, Mingxi; Zong, Yujin

doi:10.1039/c9nr01691k

Cited by 45 publications

(35 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Research on organic sonosensitizers has played a vital role in the discovery and development of drugs for many years . Similar to organic photosensitizers, organic sonosensitizers also generate ROS by activating the organic molecules from the ground state to the excited state under ultrasonic stimulation . Therefore, part of the basic design of sonosensitizers is derived from photosensitizers .…”

Section: Organic Sonosensitizersmentioning

confidence: 99%

Ultrasound‐Activated Sensitizers and Applications

et al. 2020

View full text Add to dashboard Cite

Modalities for photo‐triggered anticancer therapy are usually limited by their low penetrative depth. Sonotheranostics especially sonodynamic therapy (SDT), which is different from photodynamic therapy (PDT) by the use of highly penetrating acoustic waves to activate a class of sound‐responsive materials called sonosensitizers, has gained significant interest in recent years. The effect of SDT is closely related to the structural and physicochemical properties of the sonosensitizers, which has led to the development of new sound‐activated materials as sonosensitizers for various biomedical applications. This Review provides a summary and discussion of the types of novel sonosensitizers developed in the last few years and outlines their specific designs and the potential challenges. The applications of sonosensitizers with various functions such as for imaging and drug delivery as well as in combination with other treatment modalities would provide new strategies for disease therapy.

show abstract

Section: Organic Sonosensitizersmentioning

confidence: 99%

Ultrasound‐Activated Sensitizers and Applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, drug release was also measured in the absence and presence of the free radical scavengers NaN3, UV absorption spectrum was tested to reveal the stability of IR780 (in IR780/PTL‐NPs) under US irradiation. Ultrasonic cavitation was measured using TA method as previously described …”

Section: Methodsmentioning

confidence: 99%

“…US has been considered to be an attractive driving force to seek targeted amplification of nanodrugs therapeutic effects with its inherent advantages of precise spatio‐temporal control, noninvasive, and superior tissue penetration depth . It was to be a safe and attractive external motivation compared to the other external stimuli; furthermore, US‐induced SDT could enhanced the permeability of blood vessels and tumor cell membranes, thereby improving the concentration and distribution of drugs in tumor is the premise of effective chemotherapy . For example, Wang et al designed a US‐triggered porphyrin‐phospholipid‐liposome nanocarrier for synergistic SDT/chemotherapy, and Ding et al developed methacrylated hyaluronic acid (m‐HA)‐modified DOX‐loaded mesoporous silica nanoparticles (MSNs) that release the drug upon sonodynamic stimulation .…”

Section: Introductionmentioning

confidence: 99%

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

Dong

Guo

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) not only has greater tissue‐penetrating depth compared to photo‐stimulated therapies, but also can also trigger rapid drug release to achieve synergistic sonochemotherapy. Here, reactive oxygen species (ROS)‐responsive IR780/PTL‐ nanoparticles (NPs) are designed by self‐assembly, which contain ROS‐cleavable thioketal linkers (TL) to promote paclitaxel (PTX) release during SDT. Under ultrasound (US) stimulation, IR780/PTL‐NPs produce high amounts of ROS, which not only induces apoptosis in human glioma (U87) cells but also boosts PTX released by decomposing the ROS‐sensitive TL. In the U87 tumor‐bearing mouse model, the IR780/PTL‐NPs releases the drug at the target sites in a controlled manner upon US irradiation, which significantly inhibits tumor growth and induces apoptosis in the tumor tissues with no obvious toxicity. Taken together, the IR780/PTL‐NPs are a novel platform for sonochemotherapy, and can control the spatio‐temporal release of chemotherapeutic drugs during SDT.

show abstract

“…Therefore, it is necessary that administered drugs act on the cancerous tissue without affecting other normal cells and maintain a stable state in in vivo microenvironments until they are delivered. To this end, HA, with the various advantages discussed earlier, has been applied for drug delivery of anticancer drugs [32][33][34][35][36]. In general, anticancer drugs have been conjugated with HA at the carboxyl group and hydroxyl group through functional groups of the drug itself or conjugate linkers, such as ester linkers and amide linkers ( Figure 2).…”

Section: Ha-drug Conjugatesmentioning

confidence: 99%

Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

Lee

Kang

Jeong

et al. 2020

Cancers

104

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a natural mucopolysaccharide and has many useful advantages, including biocompatibility, non-immunogenicity, chemical versatility, non-toxicity, biodegradability, and high hydrophilicity. Numerous tumor cells overexpress several receptors that have a high binding affinity for HA, while these receptors are poorly expressed in normal body cells. HA-based drug delivery carriers can offer improved solubility and stability of anticancer drugs in biological environments and allow for the targeting of cancer treatments. Based on these benefits, HA has been widely investigated as a promising material for developing the advanced clinical cancer therapies in various formulations, including nanoparticles, micelles, liposomes, and hydrogels, combined with other materials. We describe various approaches and findings showing the feasibility of improvement in theragnosis probes through the application of HA.

show abstract

Enhanced anti-tumor efficacy of hyaluronic acid modified nanocomposites combined with sonochemotherapy against subcutaneous and metastatic breast tumors

Abstract: Schematic illustration of sonochemotherapy using HA-modified nanocomposites.

Cited by 45 publications

References 46 publications

Ultrasound‐Activated Sensitizers and Applications

Ultrasound‐Activated Sensitizers and Applications

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

Contact Info

Product

Resources

About